Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers. 
Via Benzinga
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. 
Via InvestorPlace
A patient’s story: Managing ulcerative colitis symptoms from diagnosis to treatment
(BPT) - Content sponsored and provided by Pfizer. Tiffany partnered with Pfizer to share her experience living with moderate to severe ulcerative colitis (UC). 
Via Brandpoint
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. 
Via Investor's Business Daily
2 Beaten-Down Growth Stocks to Buy Without Hesitation in the 2024 Bull Market
Price only tells you part of the story. 
Via The Motley Fool
7 Dividend Stocks to Buy Now: June 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
How Is The Market Feeling About Pfizer?
Via Benzinga
Is It Too Late to Buy Pfizer Stock?
It's no secret that the last year has been punishing. 
Via The Motley Fool
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
It doesn't take much to boost your passive income stream with these top dividend-paying stocks. 
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
You won't need much money to start investing in these great stocks. 
Via The Motley Fool
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields. 
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Skip Meme Mania: 3 Undervalued Blue-Chip Stocks for Steady Returns
These are the undervalued blue-chip stocks to buy, as they represent companies with strong fundamentals and robust cash flow outlooks. 
Via InvestorPlace
Supreme Court Upholds 2017 Tax On Foreign Profits For US Businesses
US Supreme Court upholds 2017 tax on foreign business income, citing Congress' constitutional power to tax. Justices Kavanaugh, Thomas, and Gorsuch dissented. 
Via Benzinga
3 Underrated Dividend Stock Machines to Turbocharge Your Income
If you are a passive income investor, take a look at these underrated dividend stocks to buy for steady income. 
Via InvestorPlace
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries. 
Via InvestorPlace
Palantir, Oracle, Pfizer Chiefs Lobby US Lawmakers For Israel's Support Amid Hamas Attack, Hostage Crisis
CEOs of Palantir, Oracle, and Pfizer lobbied US senators for support of Israel during Gaza invasion and discussed solutions for hostages held by Hamas. 
Via Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
These two pharma stocks are beloved by income investors. 
Via The Motley Fool
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced... 
Via Benzinga
Exposures Product Safety
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for advanced non-small cell lung cancer and HR+/HER2-negative breast cancer. 
Via Benzinga
Exposures Product Safety
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
Kansas has filed a lawsuit against Pfizer, Inc., alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine, resulting in consumer protection violations and... 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Exposures COVID-19
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.